All In Biotech

Drug Trial Radar · NCT00061919

Carboplatin and Etoposide With or Without Thalidomide in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer

A Phase III Randomized, Double Blind, Placebo Controlled Trial Of Carboplatin/Etoposide With Or Without Thalidomide In Small Cell Lung Cancer (Study 12)

Last checked: Nov 20, 2026Latest source record: Mar 16, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 724 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

724

Actual

Start

Apr 2003

Primary completion

Feb 2007

Study completion Jul 2007

Sponsor

Lead sponsor
University College, LondonAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 6, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy such as carboplatin and etoposide use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. It is not yet known if combination chemotherapy is more effective with or without thalidomide in treating small cell lung cancer. PURPOSE: This randomized phase III trial is studying carboplatin, etoposide, and thalidomide to see how well they work compared to carboplatin and etoposide in treating patients with limited- or extensive-stage small cell lung cancer.

Conditions

  • Lung Cancer

Interventions

  • Carboplatin, etoposide & thalidomideDrug

    Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral thalidomide daily beginning on day 1 for up to 24 months.

  • Carboplatin, etoposide & placeboDrug

    Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral placebo daily beginning on day 1 for up to 24 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Survival at 2 years after study randomizationTime frame: 0-2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University College of London Hospitals

    London, England, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.